Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...

Compare Zepbound and Wegovy to understand how one hormone vs two impacts weight loss, appetite control, side effects, and ...

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

Joe Budden discusses using Zepbound, fitness changes, and health awareness during an appearance on 'Club Shay Shay.' ...

Eli Lilly and Co. shares soared in midday trading Wednesday after the drugmaker reported fourth-quarter results that topped ...

Menopause can accelerate age-related weight gain, increasing a woman’s odds of becoming overweight or obese, researchers said in background notes. The change of life also can cause symptoms like hot ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Feb 11 (Reuters) - Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials. "We are exploring ...

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are prescription drugs used to treat different conditions. Zepbound and Mounjaro are not available as generic drugs. The two drugs have some ...